We read with interest the paper by Tampakakis et al.
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FIGURE 1 Flexible Hazard Ratio Function of Diastolic Pulmonary Gradient as a Predictor of Death
Graph depicting diastolic pulmonary gradient at baseline plotted against the log hazard ratio of death. Dashed lines mark confidence intervals of the hazard functions. 
Measurement to Predict Survival: The Case of Diastolic Pulmonary Gradient
When I revived the diastolic pressure gradient (DPG), I
never thought of introducing a new prognostic marker (1). The purpose was only to improve the diagnosis of pulmonary vascular disease in heart failure (HF).
However, a subsequent report by Gerges et al. (2) showed that an increased DPG is associated with a shorter survival in these patients. Thus Gerges et al. (2) comforted the notion that a high DPG phenotypes a subset of patients with HF and severe pulmonary vascular disease evolving much alike pulmonary arterial hypertension.
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